Adult-onset neuronal intranuclear inclusion disease, with both stroke-like onset and encephalitic attacks: a case report

Abstract

Background

Neuronal intranuclear inclusion disease (NIID) is a neurodegenerative disease, the clinical manifestations of which are complex and easily misdiagnosed. NIID clinical characteristics are varied, affecting the central and peripheral nervous systems and autonomic nerves. In this study, we present an NIID case with both stroke-like onset and encephalitic attacks, which is a rare case report.

Case presentation

A 68-year-old Chinese female presented with sudden aphasia and limb hemiplegia as the first symptoms, as well as fever, cognitive impairment and mental irritability from encephalitic attacks. During hospitalization, a brain magnetic resonance imaging (MRI) examination detected high signal intensity from diffusion-weighted imaging (DWI) of the bilateral frontal grey matter-white matter junction. Electrophysiological tests revealed the main site of injury was at the myelin sheath in the motor nerves. A skin biopsy revealed eosinophilic spherical inclusion bodies in the nuclei of small sweat gland cells, fibroblasts and fat cells, whilst immunohistochemistry revealed that p62 and ubiquitin antibodies were positive. From genetic analyses, the patient was not a carrier of the fragile X mental retardation 1 (FMR1) permutation, but repeated GGC sequences in the NOTCH2NLC gene confirmed an NIID diagnosis. Through antipsychotic and nutritional support therapy, the patient’s symptoms were completely relieved within 3 weeks.

Conclusions

This report of an NIID case with both stroke-like onset and encephalitic attacks provides new information for NIID diagnoses, and a comprehensive classification of clinical characteristics.

Background

Neuronal intranuclear inclusion disease (NIID) is a chronic progressive neurodegenerative disorder, characterized by eosinophilic transparent inclusions in the central and peripheral nervous systems, and internal organs [1, 2]. Currently, the etiology and pathogenesis of NIID remains unclear. The pathogenesis of NIID is unknown. Immunohistochemically, intranuclear inclusions are positive for ubiquitin and ubiquitin related proteins, including p62, SUMO1, FUS, MYO6, and OPTN-C, suggesting the ubiquitin-proteasome pathway in the nucleus plays a role in NIID [3–7]. In addition, GGC repeat expansions in the 5′ untranslated region (5′ UTR) of the NOTCH2NLC (Notch 2 N-terminal like C) gene are also associated with NIID mechanisms [8–11].

Similarly, NIID clinical characteristics are varied, affecting the central and peripheral nervous systems and autonomic nerves. Sporadic NIID emerges between 51 and 76 years of age [12]. Due to this variability in clinical symptoms, NIID is considered a heterogeneous disease [13]. Patients frequently manifest with dementia (94.7%), muscle weakness (27%), sensory disturbances (28.6%), autonomic nerve dysfunction, ataxia, epilepsy, paroxysmal disturbances in consciousness (39.5%) and Parkinsonism [14]. In recent years, NIID has been diagnosed by skin biopsy, magnetic resonance imaging (MRI) and genetic testing.

We report adult-onset NIID in a patient who manifested with both aphasia and limb hemiplegia, as the first symptoms. During hospitalization, she also developed fever, reversible cognitive impairment and mental irritability from encephalitic attacks. This case report describes a rare clinical manifestation of NIID, which may be helpful in updating our understanding of NIID clinical characteristics for clinicians.

Case presentation

A 68-year-old, right handed Chinese female of Han nationality, endured 3 years of untreated hypertension. She denied a history of smoking and diabetes. She had no family history of NIID or any other neurodegenerative disease. She was admitted to hospital, complaining of sudden aphasia and right limb weakness in the previous 4 h. In the past 7 years, the patient had recurrent aphasia and two episodes of limb hemiparesis, and was diagnosed with “transient ischemic attack” in 2012 and 2018. During hospitalization in 2012, she showed a sudden weakness in the right limb. This lasted 2 h and recovered without treatment. In 2018, the patient showed sudden aphasia and weakness in the right limb, which relived itself in 3 h. During these hospitalizations, the patient developed no mental abnormalities, but did have a fever > 38 °C. Each time, she was given anti-platelet aggregation therapy and supportive treatment such as vitamin B and C supplements. For most of the time, the patient looked after herself; she communicated well and was able to walk normally, however, in the recent 6 months, she suffered with memory loss and had issues with counting.

Upon admission to hospital, a physical examination revealed a temperature of 36.6 °C, a pulse of 90 beats/min, a breath rate of 20 times/min, and a blood pressure of 196/106 mmHg. The patient’s consciousness was normal, but she was unable to cooperate during the examination, and she also had mixed aphasia. She also had central facial and tongue paralysis on her left side. Her right limb muscle strength was 4.5/5.0. The tendon reflex of her extremities was active, meningeal irritation was negative, and the right Babinski and Chaddock signs were positive. The patient was unable to cooperate during sensory system and ataxia examinations.

On the 3rd day after admission, the patient developed new symptoms: fever and an exacerbation of right limb weakness. A physical examination revealed a temperature of 38.8 °C, and a motor examination revealed a right limb muscle strength of 3/5. Her meningeal irritation and right Babinski and Chaddock signs changed to negative. On the 5th day after admission, the patient had mental irritability and cognitive impairment. On the 20th day after admission, without any treatment which could have resulted in cognitive improvement, the patient’s limb muscle strength returned to normal, she had no mental abnormalities, but her memory and counting skills were still poor.

Computed tomography angiography (CTA) revealed no intracranial aortic stenosis or occlusion. On the 5th day after admission, a T2/Flair sequence of a skull magnetic resonance imaging (MRI) scan revealed abnormal signals in the white matter region of the brain, and high signal intensity in the bilateral frontal grey matter-white matter junction, by diffusion-weighted imaging (DWI) (Fig. 1a, c). The patient had a second MRI scan on the 20th day after admission, but results from both scans were not significantly different (Fig. 1b, d). During the previous two hospitalizations, due to various reasons, the patient failed to complete an MRI and electroencephalogram (EEG), but cranial computed tomography (CT) scans revealed a low-density lesion in the white matter, area-brain atrophy, and leucoencephalopathy. During each hospitalization, these symptoms worsened (Fig. 1e, f, g).

Fig. 1.

MRI scans on the 5th day after admission: a The T2/FLAIR sequence: the arrow refers to abnormal signals in the white matter region of the brain, b DWI imaging: the arrow refers to high intensity areas in the cerebral white matter and grey matter-white matter junction; the MRI was conducted on the 20th day after admission: c The T2/FLAIR sequence: the arrow refers to abnormal signals in the white matter region of the brain, d DWI imaging: the arrow refers to high intensity areas in the cerebral white matter and grey matter-white matter junction. Cranial computed tomography scans showed a low-density lesion in the white matter, area-brain atrophy, and leucoencephalopathy: e in 2012, f in 2018, and g this hospitalization

Routine blood tests revealed the patient’s leukocyte count was 12.29 × 10⁹/L (the normal range is 4.0–10.0 × 10⁹/L), and her neutrophil percentage was 89.4% (the normal range is 50–70%). Her C-reactive protein and procalcitonin levels were normal. A cerebrospinal fluid lumbar puncture examination revealed that pressure was 160 mmH2O.The number of cells in the CSF was 4.0 × 10⁶/L (the normal range is 4.0–10.0 × 10⁹/L), and a cytological examination of the cerebrospinal fluid revealed 50% lymphocytes and 50% monocytes. Biochemical tests revealed her glucose level was 3.8 mmol/L, total protein was 0.75 g/L (the normal range is 0.15–0.4 g/L), and chloride was 129.9 mmol/L (the normal range is 120-130 mmol/L).

On the 20th day after admission, the patient’s serial electroencephalogram (EEGs) demonstrated a low amplitude θ wave (5–7 Hz), and a few α rhythms (8–9 Hz), but no abnormal brain waves were observed. Her skin sympathetic reflexes revealed that the amplitude of her right upper limb (194.1 μV) was lower than the left (497.2 μV). Electrophysiological tests revealed that motor nerve conduction velocity of the left median nerve (47 m/s), right median nerve (49 m/s), left ulnar nerve (47 m/s), left common peroneal nerve (41 m/s) and right common peroneal nerve (40 m/s) were slow. The sensory conduction velocities of bilateral median, ulnar, and sural nerves were normal. The following scales were completed: The mini-mental state examination (MMSE) scale was 24/30, the Montreal cognitive assessment scale (MoCA) was 21/30, the frontal lobe function assessment (FAB) was 17, and the activity of daily living scale (ADL) was 21.

A skin biopsy was performed under light microscopy. Hematoxylin-eosin staining revealed eosinophilic spherical inclusion bodies in the nuclei of epithelial cells in small sweat gland cells (Fig. 2a). Immunohistochemical staining revealed that inclusion bodies were positive for p62 and ubiquitin staining (Fig. 2b and c). Genetic testing revealed the patient was not a carrier of the fragile X mental retardation 1 (FMR1) premutation. Genetic examination was performed using repeat-primed PCR (RP-PCR) and GC-rich PCR (GC-PCR). We observed 102 GGC repeats in the 5’UTR of NOTCH2NLC (the normal range is < 40 [15]) (Fig. 2d, e).

Fig. 2.

Skin biopsy samples underwent immunohistochemical staining: a hematoxylin-eosin staining (× 200 magnification), the arrows refer to eosinophilic spherical inclusion bodies in the nuclei of epithelial cells in small sweat gland cells; b anti-p62 immunohistochemical staining (arrows, × 200 magnification) and c anti-ubiquitin immunohistochemical staining (arrows, × 200 magnification). d Electropherograms showing GC-rich regions using PCR and repeat-primed PCR assays. e GC-rich PCR (GC-PCR) indicated the patient had 102 GGC repeats in the 5’ UTR of NOTCH2NLC

During this hospitalization, the patient was given symptomatic treatment including an anti-antipsychotic (olanzapine 10 mg/daily) and nutrition support therapy, after which, her symptoms were relieved within 3 weeks. After discharge, a telephone follow-up at 3 months revealed the patient no longer had limb paralysis and mental hemiplegia as the first symptoms, and also fever, cognitive impairment and mental irritability from encephalitic attacks.

Discussion and conclusions

In previous studies, Lin et al. reported a NIID patient with stroke-like onset symptoms, such as sudden limb weakness, and Li et al. reported a patient with multiple reversible encephalitic attacks, with light-headed episodes, central facial paralysis, unstable gait, aphasia, nausea, vomiting and loss of consciousness [16, 17]. However, no cases have yet been reported with stroke-like onset symptoms and encephalitic attacks. In this study, we reported such an NIID case with sudden aphasia and limb hemiplegia as the first symptoms, and also fever, cognitive impairment and mental irritability from encephalitic attacks.

A cranial MRI of NIID typically shows the following characteristic manifestations: (i) A DWI shows the curvilinear high signal of the cortex and medulla junction are specific [18]. The lesions progress from the bilateral frontal lobe to the parietal occipital lobe. The coexistence of U-shaped fiber linear high signals and decreased cognitive function in the DWI cortex are considered characteristic manifestations of NIID [19]. (ii) As NIID progresses, the T2/FLAIR high signal gradually affects the entire corpus callosum. It has been speculated that the range of abnormal signals at the corpus callosum is correlated to NIID progression [19]. (iii) NIID is often associated with brain atrophy and white matter lesions, but this is not specific.

Since 2003, several studies have reported eosinophilic nuclear inclusions in skin biopsies from NIID patients [12, 13, 20, 21], therefore skin biopsies have become useful in confirming NIID diagnoses. These biopsies revealed that inclusions were circular, with perinuclear diameters of 1.5–10 μm. They were ubiquitin and p62-positive, and when viewed under electron microscopy, they consisted of fibrous materials lacking membranous structures. However, it remains unclear what role p62 may play in the pathogenesis of NIID. As a ubiquitin-binding protein, p62 has important roles in several neurodegenerative diseases, but its significance in NIID remains as yet unclear [22].

GGC repeat expansion in the 5′ UTR of the NOTCH2NLC gene is associated with NIID mechanisms [10, 23]. Studies by Sone et al. and Tian et al. have suggested that the abnormal amplification of GGC trinucleotides in NIID, provides new molecular diagnostics for an NIID genetic diagnosis [10, 15]. Deng et al. [11] revealed that the abnormal expression of NOTCH2NLC could occur in both juvenile and adult patients with NIID. Equally, fragile X-related tremor/ataxia syndrome (FXTAS) also displays similar disease features during imaging, as the clinical symptoms of both conditions are similar [24]. In East Asia, NIID appears to be more common than FXTAS, thus before definitively diagnosing NIID, the FMR1 gene must be analyzed to exclude FXTAS.

Our patient’s electrophysiological tests indicated that motor nerve conduction velocity of her limbs was slowed down. A Japanese study confirmed this in patients with NIID; these authors observed delays or reductions in the amplitude of nerve conduction velocity to varying degrees, similar to our observations [25]. Hirose et al. proposed that nerve conduction velocity and somatosensory evoked potentials may be the diagnostic basis for NIID [26].

Similar to other neurodegenerative diseases, no appropriate methods exist to definitively treat NIID pathophysiological mechanisms; only supportive therapies and symptomatic treatments are available. An NIID patient identified by Han et al., was given methylprednisolone pulse therapy (500 mg/daily) for three consecutive days, to gradually relived their symptoms [27]. In another Japanese case report, intravenous immunoglobulin (IVIg) therapy improved symptoms in a NIID patient [28]. Immunomodulatory therapy may be effective for NIID, but mechanisms must be explored in future studies. In this report, the patient’s mental irritability and cognitive impairment were improved by an anti-antipsychotic (olanzapine 10 mg/daily), suggesting disease relief may be related to the neuroprotective effects of olanzapine [29, 30].

According to our patient’s history, she suffered three episodes of limb weakness and two episodes of fever and aphasia, but she was not diagnosed due to a lack of radiographic examinations and genetic tests. We had also considered the possibility of central nervous system vasculitis or nervous system disease, but there was no evidence to support these diagnoses. The clinical heterogeneity of NIID at different stages of the disease increased the difficulty and complexity of our diagnosis.

In summary, we present a rare case of NIID with both stroke-like onset and encephalitic attacks. The patient was diagnosed based on characteristic DWI signals, intranuclear inclusions and expanded GGC repeats in NOTCH2NLC. Clinicians need to alert patients with recurrent disease stroke-like onset symptoms and/or encephalitic attack to avoid misdiagnosis.

Abbreviations

NIID

Neuronal intranuclear inclusion disease

MRI

Magnetic resonance imaging

DWI

Diffusion-weighted imaging

CT

Cranial computed tomography

CTA

Computed tomography angiography

FMR1

Fragile X mental retardation 1

FXTAS

Fragile X-related tremor/ataxia syndrome

NOTCH2NLC

Notch 2 N-terminal like C

5′ UTR

5′ untranslated region

RP-PCR

Repeat-primed PCR

GC-PCR

GC-rich PCR

IVIg

Intravenous immunoglobulin

EEG

Electroencephalogram

EEGs

Serial electroencephalogram

Authors’ contributions

YH drafted the manuscript; GJ collected and analyzed patient information; YT and LS examined the NOTCH2NLC gene; QLZ interpreted the data and edited the manuscript. The final manuscript was read and approved by all authors.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

The datasets used and/or analyzed during this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient and her next of kin when she had experienced cognitive impairment for publication of this case report. A copy of the written consent is available for review by the Editor of the journal.

Competing interests

No competing interests are declared.